Crossmark

Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus

Published Online: 2022-10-22

Published Print: 2022-12

Authors

Malla, Midhun

Fuqua, Jacob

Mukherjee, Sarbajit

Goldberg, Richard M. https://orcid.org/0000-0003-0308-8223
License Information

Text and Data Mining valid from 2022-10-22

Version of Record valid from 2022-10-22
More Information

Article History

Accepted: 9 October 2022

First Online: 22 October 2022

Compliance with Ethical Standards

:

: Midhun Malla received a grant from the National Institute of General Medical Sciences-NIH (Grant # 5U54GM104942-05) as a research scholar. The content reported in this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Midhun Malla received payments as a consultant from the following companies: QED, Astrazenaca and Natera. Jacob Fuqua declares that he has no conflict of interest. Sarbajit Mukherjee declares that he received payments from the following: Ipsen biopharmaceuticals, research support (paid to institute) from NCCN oncology. Richard Goldberg declares that he has received payments as a consultant or expert witness from the following companies: AbbVie, Advanced Chemotherapy Technologies, Astra Zeneca, Bayer, Compass Therapeutics, Eisai, G1 Therapeutics, Genentech, GSK, Innovative Cellular Therapeutics, Inspirna, Merck, Sorrento Therapeutics, Taiho, and UpToDate.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current